Research · Aug 27, 2026
Medical Device Contracting Becomes the New Gate for Device Access
TELA, Humacyte and Ambu show how hospital committees, bundled contracts and ASC pricing increasingly determine device access and revenue quality.
HUMA
Humacyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
+0.76%